http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Cheolwon Suh,Sang Hee Kim,Hyo Jung Kim,Geundoo Jang,Eun Kyung Kim,Ok Bae Ko,Shin Kim,Hee Jung Sohn,Jung Shin Lee,Wookun Kim,Jooryung Huh 대한암학회 2005 Cancer Research and Treatment Vol.37 No.5
Purpose: Autologous stem cell transplantation (ASCT) is increasingly used in patients with non-Hodgkin’s lymphoma (NHL). Various clinical parameters-wereevaluated to obtain significant predictors of the outcome following ASCT in patients with NHLMaterials and Methods: Between April 1994 and December 2003, ASCT was performed on 80 patients with NHL at the Asan Medical Center. Results: Patients had various histological subtypes and disease status. The two year progression free survival (PFS) and overall survival for all patients were 34 and 31%, respectively. A univariate analysis showed the performance status, stage, modified extranodal involvement category, International Prognostic Index (IPI) at mobilization, disease status at mobilization, and history of radiation prior to mobilization as significant predictors of the outcome following ASCT. Four risk groups, with different 2 year PFS, were identified by the age adjusted IPI at mobilization (mAAIPI): low risk 44%; low intermediate risk 40%; high intermediate risk 19%; and high risk 0% (p=.0003). A multivariate analysis revealed 3 significant factors for the PFS: disease status, prior RT and mAAIPI. Conclusion: The mAAIPI was found to be an independent predictor of the outcome of NHL patients undergoing ASCT. This powerful prognostic tool should be used to evaluate potential candidates for ASCT.
방수미,EunKyungCho,CheolwonSuh,Sung-SooYoon,ChuMyungSeong,KyungSamCho,YoonGooKang,SeonyangPark,Myung-JuAhn,YoungSukPark,DoyeunOh,정철원,SamyongKim 대한의학회 2003 Journal of Korean medical science Vol.18 No.5
We conducted a phase II multicenter trial to estimate the response and survival of patients with newly diagnosed multiple myeloma to high dose melphalan therapy followed by autologous peripheral blood stem cell transplantation. Eligible patients who had undergone induction with vincristine, adriamycin and dexamethasone (VAD) should have adequate cardiac, pulmonary and renal function (creatinine <2 mg/dL). Melphalan at 200 mg/m2 was used as a conditioning regimen. Eighty patients were enrolled from 13 centers. The median age of the patients was 53 yr (range; 20 to 68 yr). The initial stage was IA/IIA/IIB/IIIA/IIIB in 3/8/1/54/14 patients, respectively. Beta2-microglobulin, CRP and LDH were increased in 74, 42 and 34% of the patients examined. Cytogenetic data were available in 30 patients, and 6 patients showed numeric or structural abnormalities. Two therapy-related mortalities occurred from infection. Among the 78 evaluable patients, CR/PR/MR/NC/PD were achieved in 48/26/2/1/1patients, respectively. After a median follow-up of 30 months, the median overall and event-free survivals were 66 months (95% CI: 20-112) and 24 months (95% CI: 18-29), respectively. This study verifies the efficacy and feasibility of high dose melphalan therapy with autologous stem cell transplantation in newly diagnosed multiple myeloma.